10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Autolus Therapeutics, which is developing blood cancer therapies based on highly targeted CAR T cells, raised $150 million by offering 8.8 million shares at $17, the high end of the $15 to $17 range. The company planned to offer 7.8 million shares. Existing...read more
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Autolus Therapeutics, which is developing cancer therapies based on CAR-T cell technology, announced terms for its IPO on Friday. The London, United Kingdom-based company plans to raise $125 million by offering 7.8 million ADSs at a price range of $15 to...read more
US IPO Weekly Recap: Biotechs boom in a 13-deal torrent
10 IPOs brought in $1.3 billion this past week, along with 3 SPACs raising $540 million. With a flood of biotechs, most of the IPOs this week had heavy insider buying, and no revenue. They traded very well, however, averaging a 27% gain. The week's worst IPO...read more
Cancer biotech Autolus Therapeutics prices upsized IPO at $17 high end
Autolus Therapeutics, which is developing blood cancer therapies based on highly targeted CAR T cells, raised $150 million by offering 8.8 million shares at $17, the high end of the $15 to $17 range. The company planned to offer 7.8 million shares. Existing...read more
US IPO Week Ahead: Health care deals lead 11-IPO week
Helped by a strong market, the steady stream of June IPOs should continue in the week ahead with eleven companies scheduled to raise a combined $1.4 billion. SMB payments processor i3 Verticals and triple net lease REIT ...read more
Next-gen CAR-T biotech Autolus Therapeutics sets terms for $125 million IPO
Autolus Therapeutics, which is developing cancer therapies based on CAR-T cell technology, announced terms for its IPO on Friday. The London, United Kingdom-based company plans to raise $125 million by offering 7.8 million ADSs at a price range of $15 to...read more